The company was established in 2008 as a high-tech enterprise, focusing on the production and research and development of high-end pharmaceutical intermediates and health product raw materials. The main products include:HMB-CA、Sorafenib、5-Azacytosine,R-Tetrahydropapaverine-N-acety-L-leucinate, 1-Chloro-3,5-di(4-chlorbenzoyl)-2-deoxy-D-ribose , Atracurium,3-hydroxypyridine, creatine ethyl ester hydrochloride, L-valine methyl ester hydrochloride,2’-Fluoroacetophenone
more >
Year of Establishment:
Total Number of Staff:
less than 10 person
Main Competitive Advantages:
N;
Other Competitive Advantages:
Patents and Copyrights:
Business Type:
N;
R&D capacity:
Annual Turnover(USD):
Main Sales Markets:
North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa
Advantage Description: